The Rapid Rise of Gene Editing Stocks

December 23. 2020. 6 mins read

When you try not to check in on your stocks very often, life comes at you fast. Sometimes, that’s a good thing. Gene editing stocks have been on an absolute tear, at least the three we’re holding in our portfolio. Just look at the 30-day returns for the three OGs of gene editing stocks.

  • Editas (EDIT) +185%
  • Intellia Therapeutics (NTLA) +94%
  • Crispr Therapeutics (CRSP) +55%

The fact that all three stocks are rising in unison is very telling. This is not due to some company-specific event, but rather something happening across all gene-editing stocks. When a group of stocks that’s not in the same industry classification moves in unison, that’s usually a sign of hype (3D printing investors will remember this all too well.) Turns out there are other gene-editing stocks out there we’re not holding which can be found in our

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.